Screener
Rapport Therapeutics, Inc. RAPP RAP219Program External Expenses — Research And Development Expense
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Rapport Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.
The source filing: Rapport Therapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 7:30 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-333862
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For The Six Months Ended June 30, 2026 | For The Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Collaboration revenue | — | — | $20,000 | — |
| Operating expenses | ||||
| Research and development | 51,414 | 22,680 | 84,130 | 42,252 |
| Selling, general and administrative | 9,392 | 6,816 | 20,891 | 14,352 |
| Total operating expenses | 60,806 | 29,496 | 105,021 | 56,604 |
| Loss from operations | (60,806) | (29,496) | (85,021) | (56,604) |
| Other income: | ||||
| Interest income | 4,191 | 2,764 | 8,549 | 5,809 |
Item 1. Financial Statements.
FAQ
- What is Rapport Therapeutics, Inc.'s rap219program external expenses — research and development expense?
- Rapport Therapeutics, Inc. (RAPP) reported rap219program external expenses — research and development expense of $34.09M in Q2 2026.
- How has Rapport Therapeutics, Inc.'s rap219program external expenses — research and development expense changed year-over-year?
- Rapport Therapeutics, Inc.'s rap219program external expenses — research and development expense increased by 252.0% year-over-year, from $9.69M to $34.09M.
- What is the long-term trend for Rapport Therapeutics, Inc.'s rap219program external expenses — research and development expense?
- Over 2 years (2023 to 2025), Rapport Therapeutics, Inc.'s rap219program external expenses — research and development expense has grown at a 100.8% compound annual growth rate (CAGR), from $10.2M to $41.14M.
- What does rap219program external expenses — research and development expense mean?
- This metric represents the direct external costs incurred for the research and development activities specifically associated with the RAP219 clinical program. It captures third-party expenditures such as contract research organization fees, clinical trial site costs, and manufacturing expenses dedicated to advancing this specific therapeutic candidate. Monitoring this figure allows investors to track the capital intensity and development velocity of the company's primary pipeline assets.
Ask your AI about Rapport Therapeutics, Inc.'s rap219program external expenses — research and development expense.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude